[go: up one dir, main page]

DE60141043D1 - Rekombinante anti-cd30-antikörper und deren verwendungen - Google Patents

Rekombinante anti-cd30-antikörper und deren verwendungen

Info

Publication number
DE60141043D1
DE60141043D1 DE60141043T DE60141043T DE60141043D1 DE 60141043 D1 DE60141043 D1 DE 60141043D1 DE 60141043 T DE60141043 T DE 60141043T DE 60141043 T DE60141043 T DE 60141043T DE 60141043 D1 DE60141043 D1 DE 60141043D1
Authority
DE
Germany
Prior art keywords
proteins
hodgkin
disease
antibodies
hefi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60141043T
Other languages
English (en)
Inventor
Joseph A Francisco
Grant Risdon
Alan F Wahl
Clay B Siegall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seagen Inc
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24910311&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60141043(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Application granted granted Critical
Publication of DE60141043D1 publication Critical patent/DE60141043D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE60141043T 2000-11-28 2001-11-28 Rekombinante anti-cd30-antikörper und deren verwendungen Expired - Lifetime DE60141043D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/724,406 US7090843B1 (en) 2000-11-28 2000-11-28 Recombinant anti-CD30 antibodies and uses thereof
PCT/US2001/044811 WO2002043661A2 (en) 2000-11-28 2001-11-28 Recombinant anti-cd30 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
DE60141043D1 true DE60141043D1 (de) 2010-02-25

Family

ID=24910311

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60141043T Expired - Lifetime DE60141043D1 (de) 2000-11-28 2001-11-28 Rekombinante anti-cd30-antikörper und deren verwendungen

Country Status (12)

Country Link
US (1) US7090843B1 (de)
EP (1) EP1347730B2 (de)
JP (1) JP4303964B2 (de)
AT (1) ATE454124T1 (de)
AU (2) AU2002236518B2 (de)
CA (1) CA2430135C (de)
CY (1) CY1110700T1 (de)
DE (1) DE60141043D1 (de)
DK (1) DK1347730T4 (de)
ES (1) ES2339333T5 (de)
PT (1) PT1347730E (de)
WO (1) WO2002043661A2 (de)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018194A1 (en) * 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US7090843B1 (en) † 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
US20050123536A1 (en) * 2001-11-20 2005-06-09 Che-Leung Law Treatment of immunological disorders using anti-dc30 antibodies
CA2471645A1 (en) * 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
KR100668538B1 (ko) 2002-01-09 2007-01-16 메다렉스, 인코포레이티드 Ｃｄ３０에 대한 인간 모노클로날 항체
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
PT2357006E (pt) 2002-07-31 2016-01-22 Seattle Genetics Inc Conjugados de fármacos e sua utilização para tratamento do cancro, de uma doença autoimune ou de uma doença infeciosa
PT1725249E (pt) 2003-11-06 2014-04-10 Seattle Genetics Inc Compostos de monometilvalina capazes de conjugação a ligandos
WO2006039644A2 (en) 2004-10-01 2006-04-13 Medarex, Inc. Methods of treating cd30 positive lymphomas
NZ560209A (en) 2005-02-18 2009-04-30 Medarex Inc Monoclonal antibodies against CD30 lacking in fucosyl residues
AU2006302254B2 (en) 2005-10-06 2011-05-26 Xencor, Inc. Optimized anti-CD30 antibodies
US8257706B2 (en) * 2006-08-25 2012-09-04 Seattle Genetics, Inc. CD30 binding agents and uses thereof
CN111499748A (zh) 2007-07-16 2020-08-07 健泰科生物技术公司 抗cd79b抗体和免疫偶联物及使用方法
NZ583318A (en) 2007-07-16 2012-07-27 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugates and methods of use
EP2185188B1 (de) 2007-08-22 2014-08-06 Medarex, L.L.C. Ortsspezifische bindung von wirkstoffen oder anderen mitteln an gentechnisch hergestellte antikörper mit c-terminalen erweiterungen
EP2211885B1 (de) 2007-10-12 2015-07-29 Seattle Genetics, Inc. Kombinationstherapie mit antikörper-arzneimittel-konjugaten
ES2587392T3 (es) 2008-01-31 2016-10-24 Genentech, Inc. Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
DK2326350T3 (da) 2008-09-08 2013-12-16 Psma Dev Company L L C Forbindelser til at dræbe psma-udtrykkende, taxanresistente cancerceller
CA3159253A1 (en) 2009-01-09 2010-07-15 Seagen Inc. Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
KR101224468B1 (ko) * 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
ES2730941T7 (es) 2010-10-22 2020-05-27 Seattle Genetics Inc Efectos sinérgicos entre los conjugados de conjugados anticuerpo-fármaco a base de auristatina e inhibidores de la ruta PI3K-AKT-mTOR
US9764038B2 (en) 2011-12-23 2017-09-19 Innate Pharma Enzymatic conjugation of antibodies
PL3431492T3 (pl) * 2012-04-27 2021-07-05 Novo Nordisk A/S Białka wiążące antygen ludzkiego ligandu CD30
US10132799B2 (en) 2012-07-13 2018-11-20 Innate Pharma Screening of conjugated antibodies
US10195288B2 (en) 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
WO2014061277A1 (ja) 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
EP3564259A3 (de) 2012-11-09 2020-02-12 Innate Pharma Kennungen für tgase-vermittelte konjugation
CN105849086B (zh) 2012-11-24 2018-07-31 杭州多禧生物科技有限公司 亲水性链接体及其在药物分子和细胞结合分子共轭反应上的应用
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
AU2013364065B2 (en) 2012-12-21 2018-10-04 Altrubio Inc. Hydrophilic self-immolative linkers and conjugates thereof
US10611824B2 (en) 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
MX2015012562A (es) 2013-03-15 2016-06-21 Abbvie Inc Purificacion de conjugados anticuerpo-farmaco (cafs).
HK1219044A1 (zh) 2013-03-15 2017-03-24 艾伯维德国有限责任两合公司 抗egfr抗体药物偶联物制剂
KR20150139955A (ko) 2013-04-09 2015-12-14 보스톤 바이오메디칼, 인크. 암 치료에 사용하기 위한 2-아세틸나프토[2,3-b]푸란-4,9-디온
WO2014202773A1 (en) 2013-06-20 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
CA2914189C (en) 2013-06-21 2023-03-14 Innate Pharma Enzymatic conjugation of polypeptides
AU2014337555C1 (en) 2013-10-15 2021-01-28 Seagen Inc. PEGylated drug-linkers for improved Ligand-Drug Conjugate pharmacokinetics
AU2015210578B2 (en) 2014-01-29 2020-04-16 Jiangsu Hengrui Medicine Co., Ltd. Ligand-cytotoxic drug conjugate, preparation method therefor, and uses thereof
CN114262344A (zh) 2014-02-28 2022-04-01 杭州多禧生物科技有限公司 带电荷链接体及其在共轭反应上的应用
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
US9950077B2 (en) 2014-06-20 2018-04-24 Bioalliance C.V. Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof
CA2954934C (en) 2014-06-30 2023-09-26 Glykos Finland Oy Drug derivative and conjugates
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
RS60349B8 (sr) 2014-09-23 2022-10-31 Hoffmann La Roche Postupak upotrebe anti-cd79b imunokonjugata
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
HRP20200640T1 (hr) 2015-05-30 2020-07-10 Molecular Templates, Inc. De-imunizirane, okosnice podjedinice shiga toksina a i molekule koje ciljaju stanice koje ih sadrže
HK1245632A1 (zh) 2015-06-03 2018-08-31 波士顿生物医药有限公司 包含癌症干性抑制剂的组合物和用於治疗癌症的免疫治疗剂
AU2015242210A1 (en) 2015-06-15 2017-12-07 Hangzhou Dac Biotech Co., Ltd Hydrophilic linkers for conjugation
CA2991973C (en) 2015-07-12 2021-12-07 Suzhou M-Conj Biotech Co., Ltd. Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
WO2017027392A1 (en) 2015-08-07 2017-02-16 Novartis Ag Treatment of cancer using chimeric cd3 receptor proteins
US10711282B2 (en) 2015-11-23 2020-07-14 Novartis Ag Optimized lentiviral transfer vectors and uses thereof
EP3397756B1 (de) 2015-12-30 2023-03-08 Novartis AG Immuneffektorzelltherapien mit verbesserter wirksamkeit
CN108713026B (zh) 2016-01-08 2023-01-06 美国全心医药生技股份有限公司 四价抗psgl-1抗体及其用途
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
EP3433278A4 (de) 2016-03-25 2019-11-06 Seattle Genetics, Inc. Verfahren zur herstellung von pegylierten wirkstoff-linkern und zwischenprodukten davon
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
NZ752394A (en) 2016-11-14 2021-07-30 Hangzhou Dac Biotech Co Ltd Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
WO2018089890A1 (en) 2016-11-14 2018-05-17 Millennium Pharmaceuticals, Inc. Non-adult human dosing of anti-cd30 antibody-drug conjugates
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
CN106854245A (zh) * 2016-12-28 2017-06-16 无锡傲锐东源生物科技有限公司 抗cd30蛋白单克隆抗体及其用途
EP4043485A1 (de) 2017-01-26 2022-08-17 Novartis AG Cd28-zusammensetzungen und verfahren für chimäre antigenrezeptortherapie
JP2020506700A (ja) 2017-01-31 2020-03-05 ノバルティス アーゲー 多重特異性を有するキメラｔ細胞受容体タンパク質を用いた癌の治療
US20200048359A1 (en) 2017-02-28 2020-02-13 Novartis Ag Shp inhibitor compositions and uses for chimeric antigen receptor therapy
WO2018158716A1 (en) 2017-03-02 2018-09-07 Cadila Healthcare Limited Novel protein drug conjugate formulation
SG11201908325PA (en) 2017-03-24 2019-10-30 Seattle Genetics Inc Process for the preparation of glucuronide drug-linkers and intermediates thereof
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
EP3694559A2 (de) 2017-10-11 2020-08-19 Seattle Genetics, Inc. Verfahren zur verminderung der nebenwirkungen einer anti-cd30-antikörper-wirkstoff-konjugattherapie
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
EP3700933A1 (de) 2017-10-25 2020-09-02 Novartis AG Gegen cd32b gerichtete antikörper und verfahren zur verwendung davon
RU2020116579A (ru) 2017-10-25 2021-11-25 Новартис Аг Способы получения клеток, экспрессирующих химерный антигенный рецептор
WO2019089798A1 (en) 2017-10-31 2019-05-09 Novartis Ag Anti-car compositions and methods
WO2019089870A1 (en) 2017-11-01 2019-05-09 Seattle Genetics, Inc. Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
CN110305211A (zh) 2018-03-20 2019-10-08 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
JP2021518397A (ja) 2018-03-23 2021-08-02 シージェン インコーポレイテッド 固形腫瘍を治療するためのチューブリン破壊剤を含む抗体薬物コンジュゲートの使用
EP3784351A1 (de) 2018-04-27 2021-03-03 Novartis AG Car-t-zelltherapien mit erhöhter wirksamkeit
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
EP3801769A1 (de) 2018-05-25 2021-04-14 Novartis AG Kombinationstherapie mit therapien mit chimärem antigen-rezeptor (car)
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
EP3856777A1 (de) 2018-09-24 2021-08-04 The Medical College of Wisconsin, Inc. Anti-cd30-antikörper und verfahren zur verwendung
CN118903456A (zh) 2018-09-26 2024-11-08 江苏恒瑞医药股份有限公司 依喜替康类似物的配体-药物偶联物及其制备方法和应用
KR20210069679A (ko) 2018-10-01 2021-06-11 씨젠 인크. 항-cd30 항체 약물 컨쥬게이트 요법을 사용하여 말초 t 세포 림프종을 치료하는 방법
US11279698B2 (en) 2018-11-20 2022-03-22 Cornell University Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
US20220144807A1 (en) 2019-02-15 2022-05-12 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
BR112021015672A2 (pt) 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos
AU2020271123A1 (en) 2019-04-10 2021-11-25 Elevatebio Technologies, Inc. FLT3-specific chimeric antigen receptors and methods of using the same
EP4032892A4 (de) 2019-09-18 2023-10-18 Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Camptothecin-derivat und konjugat davon
CN114728046A (zh) 2019-09-25 2022-07-08 思进公司 联合抗cd30 adc、抗pd-1和化疗以治疗血液癌症
WO2021067820A1 (en) 2019-10-04 2021-04-08 Seagen Inc. Formulation of antibody-drug conjugate
MX2022003930A (es) 2019-10-04 2022-07-04 Seagen Inc Conjugados de péptido de camptotecina.
IL292685A (en) 2019-11-04 2022-07-01 Seagen Inc Anti-cd30 antibody-drug conjugates and their use for the treatment of hiv infection
EP4076660A1 (de) 2019-12-20 2022-10-26 Novartis AG Verwendung von anti-tgf-beta-antikörpern und checkpoint-inhibitoren zur behandlung von proliferativen erkrankungen
EP4094779A4 (de) 2020-01-22 2023-11-22 Shanghai Senhui Medicine Co., Ltd. Wirkstoffkonjugat von eribulinderivat, verfahren zu seiner herstellung und seine verwendung in der medizin
CN115697400A (zh) 2020-01-31 2023-02-03 思进股份有限公司 抗cd30抗体-药物缀合物及其用于治疗非霍奇金淋巴瘤的用途
WO2021190581A1 (zh) 2020-03-25 2021-09-30 江苏恒瑞医药股份有限公司 一种含抗体药物偶联物的药物组合物及其用途
EP4130045A4 (de) 2020-03-25 2023-12-27 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Herstellungsverfahren für antikörper-arzneimittelkonjugat
EP4132588A1 (de) 2020-04-10 2023-02-15 Seagen Inc. Ladungsvariantenlinker
MX2022014225A (es) 2020-05-13 2023-02-09 Seagen Inc Metodos para tratar cancer utilizando una combinacion de conjugados de farmaco-anticuerpo anti-cd30.
KR20230024967A (ko) 2020-06-11 2023-02-21 노파르티스 아게 Zbtb32 억제제 및 이의 용도
JP2023531676A (ja) 2020-06-23 2023-07-25 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
MX2023008327A (es) 2021-01-15 2023-08-22 Seagen Inc Anticuerpos inmunomoduladores de anticuerpo-farmaco.
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2022226100A1 (en) 2021-04-20 2022-10-27 Seagen Inc. Modulation of antibody-dependent cellular cytotoxicity
AU2022267891A1 (en) 2021-04-27 2023-11-09 Novartis Ag Viral vector production system
EP4346906A1 (de) 2021-05-28 2024-04-10 Seagen Inc. Anthracyclin-antikörperkonjugate
CA3236735A1 (en) 2021-10-29 2023-05-04 Seagen Inc. Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate
KR20240095442A (ko) 2021-11-03 2024-06-25 항저우 디에이씨 바이오테크 씨오, 엘티디 항체의 특이적 접합
CN114891101B (zh) * 2021-12-02 2023-06-16 吉林省农业科学院 一种牛肌肉生长抑制素蛋白单克隆抗体及其应用
WO2023178289A2 (en) 2022-03-17 2023-09-21 Seagen Inc. Camptothecin conjugates
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2023215740A1 (en) 2022-05-06 2023-11-09 Seagen Inc. Immunomodulatory antibody-drug conjugates
AU2023365454A1 (en) 2022-10-18 2025-04-03 Meiji Seika Pharma Co., Ltd. Therapeutic agent for t cell malignancies
AU2023369684A1 (en) 2022-10-26 2025-04-17 Novartis Ag Lentiviral formulations
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
AU2024238898A1 (en) 2023-03-22 2025-10-16 Salubris Biotherapeutics, Inc. Anti-5t4 antigen binding domains, antibody-drug conjugates and methods of use thereof
TW202500126A (zh) 2023-05-24 2025-01-01 美商金橘生物科技公司 雜環化合物及其用途
TW202535940A (zh) 2023-10-24 2025-09-16 美商思進公司 化學治療化合物及使用方法
WO2025096626A1 (en) 2023-10-31 2025-05-08 Seagen Inc. Methods of treating cancers using anti-cd30 antibody-drug conjugates
WO2025149947A1 (en) 2024-01-12 2025-07-17 Seagen Inc. Antibody-drug conjugates
WO2025169056A1 (en) 2024-02-06 2025-08-14 Seagen Inc. Methods of treating cancers using anti-cd30 antibody-drug conjugates
CN119331093B (zh) * 2024-11-04 2025-07-11 武汉伊莱瑞特生物科技股份有限公司 一种抗CD30的兔源Fab抗体及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991007437A2 (en) 1989-11-20 1991-05-30 Parker, David, L. Improved cd-30 antibodies and fragments thereof
US5165923A (en) * 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease
DE4200043A1 (de) 1991-11-11 1993-05-13 Stein Harald Prof Dr Lymphoides cd30-antigen (ki-1), dessen protein- und die zugehoerige nucleotidsequenz, seine herstellung sowie mittel zur diagnose und untersuchung von tumoren
JPH07503124A (ja) 1991-06-14 1995-04-06 ゾーマ・コーポレーション 微生物によって生産される抗体断片とそれらの複合体
AU666388B2 (en) 1992-05-26 1996-02-08 Immunex Corporation Novel cytokine that binds CD30
AU689758B2 (en) 1992-10-09 1998-04-09 Advanced Tissue Sciences, Inc. Liver reserve cells
US5773247A (en) 1993-01-14 1998-06-30 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Recombinant anti-HIV antibody and process for preparing the same
JP3053873B2 (ja) * 1994-08-12 2000-06-19 イムノメディクス，インコーポレイテッド Ｂ細胞リンパ腫細胞および白血病細胞に特異的な免疫結合体およびヒト化抗体
ES2141467T5 (es) * 1995-01-18 2006-07-16 Roche Diagnostics Gmbh Anticuerpos anti-cd30 que evitan la escision proteolitica y liberacion del antigeno cd30 fijado a la membrana.
DE19543039C1 (de) 1995-11-08 1996-11-21 Medac Klinische Spezialpraep Rekombinante Liganden für das menschliche Zellmembran-Antigen CD30
DE19640733A1 (de) * 1996-10-02 1998-04-09 Abken Hinrich Verfahren zur Hemmung der unbegrenzten Profileration, Tumorbildung oder Metastasierung CD30 Antigen exprimierender Zellen
EP1283719B1 (de) 2000-04-22 2007-09-05 PharmedArtis GmbH Apoptotika
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US7090843B1 (en) † 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
US20050123536A1 (en) 2001-11-20 2005-06-09 Che-Leung Law Treatment of immunological disorders using anti-dc30 antibodies

Also Published As

Publication number Publication date
WO2002043661B1 (en) 2003-03-06
CA2430135C (en) 2012-10-02
JP2005506035A (ja) 2005-03-03
WO2002043661A2 (en) 2002-06-06
AU3651802A (en) 2002-06-11
EP1347730B1 (de) 2010-01-06
EP1347730A2 (de) 2003-10-01
PT1347730E (pt) 2010-03-03
WO2002043661A3 (en) 2003-01-16
CA2430135A1 (en) 2002-06-06
DK1347730T3 (da) 2010-02-01
ES2339333T5 (es) 2013-09-26
ATE454124T1 (de) 2010-01-15
EP1347730B2 (de) 2013-05-29
US7090843B1 (en) 2006-08-15
CY1110700T1 (el) 2015-06-10
ES2339333T3 (es) 2010-05-19
EP1347730A4 (de) 2005-08-17
AU2002236518B2 (en) 2006-10-26
JP4303964B2 (ja) 2009-07-29
DK1347730T4 (da) 2020-04-27

Similar Documents

Publication Publication Date Title
DE60141043D1 (de) Rekombinante anti-cd30-antikörper und deren verwendungen
WO2005001038A3 (en) Recombinant anti-cd30 antibodies and uses thereof
US12527843B2 (en) Immune-cell targeted bispecific chimeric proteins and uses thereof
KR102486090B1 (ko) 생체 내 내성이 높은 항체 약물 결합체
WO2003043583A3 (en) Treatment of immunological disorders using anti-cd30 antibodies
BG108514A (en) METHODS OF ADMINISTERING ANTI-TNFalpha ANTIBODIES
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
EA200501810A1 (ru) Композиция конъюгированного лекарственного средства
TR200102733T2 (tr) IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri
EA200000331A1 (ru) Фармацевтические композиции, содержащие белок плазмы
EP1921090A4 (de) Zusammensetzung genetisch modifizierter antikörper
ATE425181T1 (de) Therapeutische zusammensetzungen aus antikorper und antisens nukleinsäuren gegen serrate
MXPA03005273A (es) Anticuerpos producidos procarioticamente y sus usos.
DE60028970D1 (de) An her2 bindende peptidverbindungen
DE69520739T2 (de) Konjugat aus einem modifizierten superantigen und einer zielsuchenden verbindung und die verwendung des konjugats
IL178474A0 (en) Monoclonal antibodies to hepatocyte growth factor and pharmaceutical compositions containing the same
WO2004066931A3 (en) Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
HK1043134A1 (zh) 免疫球蛋白e的c-易扑西龍-3或者c-易扑西龍-4區衍生來的抗原決定基或模擬型，其拮抗劑，以它們的治療用途
MXPA03011499A (es) Proteinas de fusion de fce para el tratamiento de alergia y asma.
WO2002100343A3 (en) N-terminally truncated galectin-3 and antibodies for treating cancer
WO2004100882A3 (en) Inhibition of drug binding to serum albumin
NZ593171A (en) Monoclonal antibody SC104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent
WO2001072334A3 (en) Methods for treating disease with antibodies to cxcr3
CN120917048A (zh) 达雷妥尤单抗药物偶联物及其制备
WO2006110367A3 (en) Methods and compositions for mycoplasma toxins

Legal Events

Date Code Title Description
8363 Opposition against the patent